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bjectives The aim of this study was to examine the use of and outcomes associated with anti-
hrombotic strategies in patients with non–ST-segment elevation myocardial infarction (NSTEMI)
ho undergo percutaneous coronary intervention (PCI).
ackground A variety of antithrombotic strategies have been tested in clinical trials for NSTEMI pa-
ients treated with PCI.
ethods Antithrombotic strategies for NSTEMI patients undergoing PCI at 217 ACTION (Acute Coro-
ary Treatment and Intervention Outcomes Network) hospitals from January 1, 2007, to December
1, 2007, (n  11,085) were classiﬁed into commonly observed antithrombotic groups: heparin
lone (Hep alone; low-molecular-weight heparin or unfractionated heparin), bivalirudin alone (Bival
lone), heparin with glycoprotein IIb/IIIa inhibitors (Hep/GPI), and bivalirudin with GPI (Bival/GPI).
aseline characteristics are shown across treatment groups. In addition, unadjusted and adjusted
ates of in-hospital major bleeding and death are shown.
esults The standard strategy used was Hep/GPI (64%), followed by Hep or Bival alone (28%), and Bival/GPI
8%). Patients who received Hep or Bival alone were older with more comorbidities, higher baseline bleeding
nd mortality risk, and lower peak troponin. Compared with patients who received Hep/GPI , those who re-
eived Hep alone and Bival alone had lower rates of major bleeding (adjusted odds ratio [OR]: 0.52; 95% con-
dence interval [CI]: 0.42 to 0.65; adjusted OR: 0.48; 95% CI: 0.39 to 0.60; respectively), yet only patients who
eceived Bival alone had lower mortality (adjusted OR: 0.39; 95% CI: 0.21 to 0.71).
onclusions NSTEMI patients undergoing PCI are more likely to receive Bival or Hep alone when at
igher baseline bleeding risk than when at lower baseline bleeding risk. Despite higher baseline risk,
hose receiving Bival or Hep alone had less bleeding. (J Am Coll Cardiol Intv 2010;3:669–77)
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670ntithrombotic therapy is central in the treatment of the
ctivated thrombotic process in non–ST-segment eleva-
ion myocardial infarction (NSTEMI), particularly
mong moderate- or high-risk patients who undergo an
nitial invasive strategy (1–3). Yet, invasive care also
ncreases risk for bleeding due to arterial puncture and
he use of antithrombotics in the catheterization labora-
ory. Guidelines emphasize the importance of risk strat-
fication for ischemic and bleeding complications when
electing treatments to optimize short- and long-term
linical outcomes (2).
See page 678
Although outcomes associated with antithrombotic strat-
gies used in NSTEMI patients undergoing percutaneous
oronary intervention (PCI) have been well-studied in
clinical trials, the patterns of use
and outcomes in clinical practice
are less well-described (4–6).
Therefore, our objectives were to
describe: 1) the selection of an-
tithrombotic strategies among
NSTEMI patients undergoing
PCI in the ACTION (Acute
Coronary Treatment and Inter-
vention Outcomes Network)
registry as a function of patient
profiles; 2) the selection of anti-
thrombotic strategies according
to baseline risk of in-hospital
mortality and major bleeding;
and 3) the timing of antithrom-
botic therapy in relation to PCI.
Additionally, we assessed the as-
sociation between antithrom-
botic strategy and in-hospital
ajor bleeding and mortality before and after adjustment
or clinical factors.
ethods
ational Cardiovascular Data Registry’s ACTION registry.
he National Cardiovascular Data Registry’s ACTION
egistry is a national quality improvement registry of ST-
egment elevation myocardial infarction (MI) and
STEMI patients that began enrolling on January 1, 2007
7). Patients are eligible for inclusion in ACTION if they
resent within 24 h from onset of ischemic symptoms and
eceive a primary diagnosis of NSTEMI or ST-segment
levation MI. De-identified data are extracted from existing
edical records on a web-based case form by trained data
ollectors at each center. Study participation at each center
bbreviations
nd Acronyms
ival  bivalirudin
ABG  coronary artery
ypass grafting
I  confidence interval
PI  glycoprotein IIb/IIIa
nhibitor
CT  hematocrit
ep  heparin
I  myocardial infarction
STEMI  non–ST-segment
levation myocardial
nfarction
R  odds ratio
CI  percutaneous
oronary intervention
BC  red blood cellas approved by local institutional review boards. The iational Cardiovascular Data Registry has a data quality
rogram in place to ensure consistent and reliable data.
uality assurance measures, such as data quality reports and
andom site audits by trained nurse abstractors, are used to
aximize the completeness and accuracy of all records
ubmitted.
tudy population. The study population was limited to the
1,085 NSTEMI patients treated with PCI from January 1,
007 to December 31, 2007, at 217 ACTION hospitals.
he original NSTEMI population included 31,036 patients
nrolled at 275 ACTION hospitals. The following patients
ere excluded sequentially: those who did not have PCI
erformed or were missing PCI status (n  18,172); those
ith contraindications to antithrombin therapy (n  118)
r glycoprotein IIb/IIIa inhibitors (GPI) (n  506); those
ho did not receive any heparin, bivalirudin, or GPI (n 
05); those who received other less commonly used anti-
hrombotic agents (n  908); and those who received
ivalirudin before hospital stay (n  42). The remaining
1,085 PCI patients receiving antithrombotic therapy were
ivided into 4 groups of antithrombotic treatment by use of
PI and antithrombins, either alone or in combination.
atients who received any bivalirudin were classified in 1 of
he 2 bivalirudin groups—Bival alone or Bival/GPI—even
f they previously received heparin. Some patients received
ow-molecular-weight heparin or unfractionated heparin
nd were classified as Hep alone as long as use of bivalirudin
r GPI was not recorded. Patients who received GPI with
r without heparin were classified as Hep/GPI, because only
.8% received GPI alone. Therefore, the 4 antithrombotic
reatment groups were denoted as: Hep alone, Bival alone,
ep/GPI, and Bival/GPI.
eﬁnitions. Major bleeding was defined as intracranial
emorrhage, documented retroperitoneal bleed, hematocrit
HCT) drop12% (baseline to nadir12%), any red blood
ell (RBC) transfusion when baseline HCT 28%, or any
BC transfusion when baseline HCT 28% with wit-
essed bleed. The HCT cut-point of 28% was chosen to
nsure that transfusions given for baseline anemia were not
onsidered to be bleeding events. Coronary artery bypass
rafting (CABG) patients were included in the analysis, but
leeding events were censored at the time of surgery.
aseline and nadir (lowest-recorded) HCT were abstracted
n the data collection form. Blood transfusion was defined
s any nonautologous transfusion of whole or packed RBCs.
itnessed bleeding was a variable on the case report form
equiring evidence of a bleeding location. Prior-PCI timing
as defined as any time from hospital presentation up to 1 h
efore the procedure. Peri-procedure timing was defined as
h before the procedure to any time after the procedure.
e excluded patients for whom the time was unknown
rom the timing analyses. Key outcomes included in-
ospital major bleeding and death, and secondary outcomesncluded post-admission MI, heart failure, stroke, RBC
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671ransfusion, and cardiogenic shock. Other study definitions
re available at the National Cardiovascular Data Registry
ebsite.
tatistical analyses. Among patients who underwent PCI,
aseline patient demographic data, medical history, presen-
ation features, treatment patterns, and in-hospital out-
omes were presented across the 4 most common anti-
hrombotic treatment strategies. Continuous variables were
resented as medians (25th, 75th percentiles), whereas
ategorical variables were presented as percentages. Contin-
ous variables were compared with the nonparametric
ruskal-Wallis test, whereas nominal categorical variables
ere compared with chi-square tests.
Selection of patients on each antithrombotic treatment
as explored by the baseline bleeding and mortality risk
ith the Can Rapid risk stratification of Unstable angina
atients Suppress ADverse outcomes with Early implemen-
ation of the American College of Cardiology/American
eart Association guidelines (CRUSADE) bleeding score
c-index  0.72) and the CRUSADE mortality model
c-index  0.80), respectively (8–10). The CRUSADE
leeding score takes into account 8 baseline clinical presen-
ation and laboratory characteristics: sex, diabetes, periph-
ral vascular disease, heart rate, systolic blood pressure, signs
f congestive heart failure, baseline HCT 36%, and
reatinine clearance. Patients may be classified with a low
score 40) or high (score 40) bleeding risk. The
RUSADE mortality model includes systolic blood pres-
ure, age, signs of heart failure on admission, renal
nsufficiency, heart rate, dyslipidemia, prior stroke, tro-
onin ratio, prior heart failure, body mass index, diabetes,
lectrocardiogram changes (ST-segment depression and
ransient ST-segment elevation), and prior PCI. Patients
ay then be classified by tertiles of mortality risk as low
1.77%), moderate (1.77% to 4.53%), and high
4.53%). In addition, the timing of medications (i.e.,
cute clopidogrel, low-molecular-weight heparin, unfrac-
ionated heparin, bivalirudin, and GPI) and PCI was
xplored across antithrombotic therapies.
To investigate the relationship between in-hospital major
leeding and mortality and antithrombotic therapies, logis-
ic generalized estimating equations with exchangeable
orking correlation matrix were used to adjust for baseline
actors and to account for within-hospital clustering, be-
ause patients at the same hospital are more likely to have
imilar responses relative to patients at other hospitals (i.e.,
ithin-center correlation for response). This method pro-
uces estimates similar to those from ordinary logistic
egression, but their variances are adjusted for the correla-
ion of outcomes within a hospital (11). Variables included
n the model were determined through clinical input from
he investigators and included age, sex, body mass index,
ace, hypertension, diabetes, current/recent smoker, hyper-
holesterolemia, prior peripheral arterial disease, prior MI, brior PCI, prior CABG, prior heart failure, prior stroke,
ialysis, signs of heart failure on presentation, systolic blood
ressure, and heart rate at presentation. Adjusted associa-
ions for in-hospital major bleeding and mortality were
isplayed as odds ratios (ORs) with 95% confidence inter-
als (CIs), and each antithrombotic therapy was compared
ith Hep/GPI. Furthermore, a sensitivity analysis of
n-hospital major bleeding and mortality was performed
y excluding patients who received excess doses of
ow-molecular-weight heparin, unfractionated heparin,
r GPI. Lastly, the unadjusted rates of major bleeding for
ntithrombotic therapy groups were displayed across
RUSADE bleeding risk score.
A p value 0.05 was considered significant for all tests.
ll analyses were performed with SAS software (version 9.1,
AS Institute, Cary, North Carolina).
esults
e found that Hep/GPI was the most common strategy,
sed in almost two-thirds of the PCI patients (7,086 of
1,085  64%), followed by Bival alone (1,771 of 11,085
16%), Hep alone (1,365 of 11,085  12%), and
ival/GPI (863 of 11,085  8%). Among patients who
eceived Hep alone, 31% received low-molecular-weight
eparin only, 58% received unfractionated heparin only,
nd 11% received both.
emographic and baseline characteristics. The demo-
raphic data, medical histories, and baseline characteristics
f the population according to antithrombotic strategy are
hown in Table 1. Patients who received Hep alone or Bival
lone were older; more often female; more often had signs
f heart failure and higher heart rate at presentation; and
ad more cardiovascular risk factors such as hypertension,
iabetes, dyslipidemia, prior MI, congestive heart failure,
nd stroke when compared with those patients who received
ep/GPI or Bival/GPI.
leeding and mortality risks. Patients who received Hep
lone or Bival alone had a higher risk of bleeding with the
RUSADE bleeding score at baseline than those who
eceived either drug with a GPI (Table 1). In addition,
atients who received Hep alone or Bival alone were also
ore often at high risk for in-hospital mortality according
o the CRUSADE mortality risk model (Table 1).
However, when patients were stratified into 4 groups on
he basis of high and low risk of bleeding or mortality,
herapy selection differed more on the basis of the risk of
leeding than on risk of mortality (Fig. 1). In other words,
ithin the groups at low or high risk of bleeding, the use of
ifferent strategies did not vary by low or high risk of
ortality. Specifically, within the groups at low or high risk
f mortality, the use of different strategies varied primarily
y risk of bleeding. Patients at high risk of bleeding more
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672ften received Hep alone or Bival alone regardless of their
ortality risk strata.
oncomitant medications and in-hospital procedures.
edications given and in-hospital procedures performed
ithin the first 24 h (early) according to the antithrombotic
trategy are shown in Table 2. Patients who received Hep or
ival alone less often received beta-blockers, angiotensin-
onverting enzyme inhibitors, and statins within the first
4 h when compared with those patients who received
ep/GPI or Bival/GPI. Most notable, however, was the
Table 1. Baseline Characteristics According to Antithrombotic Treatment A
Hep Alone
(n  1,365) (
Age (yrs)* 66 (55, 77)
Female sex (%) 39
Race (%)
White 85
Black 8
Hispanic 3
Asian 1
Other 3
BMI (kg/m2)* 29 (25, 33)
Signs of heart failure (%) 15
Heart rate (beats/min)* 80 (68, 95)
Systolic blood pressure (mm Hg)* 145 (126, 165) 1
Creatinine clearance (ml/min)*† 75 (48, 104)
HCT baseline (%)* 41 (38, 44)
Peak troponin within 24 h (5 ULN) (%) 78
BNP (ng/ml)* 219 (77, 720) 2
ST-segment depression (%) 24
Transient ST-segment elevation (%) 5
History (%)
Hypertension 73
Diabetes 35
Hyperlipidemia 61
Congestive heart failure 11
Peripheral artery disease 10
CABG 22
PCI 31
MI 28
Stroke 7
Current/recent smoker 31
Renal insufﬁciency/dialysis 3
CRUSADE bleeding score*‡ 29 (17, 44)
CRUSADE mortality risk (%)
Low risk 42
Moderate risk 35
High risk 22
*Continuous variables are presented as median (25th, 75th percentile). †Creatinine clearance estim
ADverse outcomes with Early implementation of the American College of Cardiology/American Hea
warfarin, transferred-out patients, and missing age, sex, and race (n 10,451).
Bival alonebivalirudin only; Bival/GPIbivalirudin andglycoprotein IIb/IIIa inhibitor; BMIbod
Hep alone heparin only; Hep/GPI heparin/glycoprotein IIb/IIIa inhibitor; MImyocardial infarelatively lower use of clopidogrel overall among those Tatients who received Hep or Bival alone. Early cardiac
atheterization and PCI were less often performed in
atients who received Hep or Bival alone when compared
ith those who received Hep/GPI or Bival/GPI. The
edian time from symptom onset to cardiac catheterization
nd PCI was longer in patients who received Hep or Bival
lone than in those who received either with GPI.
ntithrombotic therapy and timing of PCI. The timing of
ntithrombotic agents in relation to the start time of PCI
mong patients who received these treatments is shown in
Patients who Underwent PCI
lone
,771)
Hep/GPI
(n  7,086)
Bival/GPI
(n  863) p Value
, 77) 61 (52, 71) 61 (52, 71) 0.0001
30 29 0.0001
0.009
86 85
7 6
3 5
1 2
2 3
, 33) 29 (26, 33) 29 (26, 33) NS
10 12 0.0001
, 94) 78 (67, 90) 77 (67, 90) 0.0001
9, 167) 145 (126, 165) 147 (126, 165) 0.003
, 107) 88 (63, 115) 87 (61, 114) 0.0001
, 44) 43 (39, 45) 43 (39, 45) 0.0001
85 87 0.0001
, 636) 163 (50, 478) 168 (55, 518) 0.0001
29 23 0.0001
7 5 0.0001
66 67 0.0001
26 29 0.0001
58 59 0.03
6 6 0.0001
7 7 0.0001
14 16 0.0001
23 24 0.0001
22 22 0.0001
5 6 0.0001
39 37 0.0001
1 1 0.0001
, 42) 21 (12, 34) 22 (12, 35) 0.0001
0.0001
52 53
33 33
13 13
y the Cockroft-Gault formula. ‡Can Rapid risk stratification of Unstable angina patients Suppress
iation guidelines (CRUSADE) bleeding score calculated on populationwithout death in 48 h, home
index; BNPbrain natriuretic peptide; CABG coronary artery bypass grafting; HCThematocrit;
CI percutaneous coronary intervention; ULN upper limit of normal.mong
Bival A
n  1
66 (56
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7
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673reated with Hep or Bival alone more often received
lopidogrel before PCI than those who were initially treated
ith a GPI. Still just approximately one-half of the Hep or
ival alone patients received clopidogrel in advance of 1 h
efore PCI start, as recommended by the guidelines. In
ddition, bivalirudin was often started at the time of PCI
nd not as an initial strategy. Unfractionated heparin was
ommonly used before PCI, regardless of the subsequent
ntithrombotic strategy. Similar results were seen for low-
eight-molecular heparin. This suggests that unfraction-
ted heparin and low-weight-molecular heparin are part of
n initial antithrombotic strategy that gets altered when
CI is planned.
linical outcomes. Unadjusted in-hospital outcome rates
ccording to antithrombotic strategy are shown in Table 4.
he OR for major bleeding after adjustment was also lower
or Hep alone (OR: 0.52; 95% CI: 0.42 to 0.65) and for
ival alone (OR: 0.48; 95% CI: 0.39 to 0.60) but not for
ival/GPI (OR: 1.23; 95% CI: 0.98 to 1.56) when com-
ared with standard therapy with Hep/GPI (reference
roup) (Fig. 2A). The rates of major bleeding increased as a
unction of CRUSADE bleeding score, yet within every
RUSADE bleeding score group, the observed rates of
ajor bleeding were lower among those treated with Hep or
ival alone compared with those treated with either Hep/
PI or Bival/GPI (Fig. 3). Lastly, only the use of Bival
lone was associated with lower in-hospital mortality after
djustment (OR: 0.39; 95% CI: 0.21 to 0.71) when com-
ared with standard therapy with Hep/GPI (reference
Figure 1. Unadjusted Rates of Antithrombotic Treatment in Low and High B
Bival alone  bivalirudin only; Bival/GPI  bivalirudin and glycoprotein IIb/IIIa
inhibitor.roup) (Fig. 2B). cIn a sensitivity analysis where any patient who received an
xcess dose of an antithrombin agent was excluded (n 
,661), adjusted rates of major bleeding remained signifi-
antly lower with Bival alone (OR: 0.46; 95% CI: 0.36 to
.60) and Hep alone (OR: 0.44; 95% CI: 0.33 to 0.59) when
ompared with standard therapy with Hep/GPI (reference
roup). However, in-hospital mortality rates were similar
mong the antithrombotic groups—Hep alone (0.97%),
ival alone (0.67%), Hep/GPI (0.85%), and Bival/GPI
1.06%) (p  NS)—and adjusted ORs for mortality when
ompared with Hep/GPI were no longer significant for
ival alone (OR: 0.47; 95% CI: 0.22 to 1.01) and Hep alone
adjusted OR: 0.64; 95% CI: 0.26 to 1.56).
iscussion
mong an NSTEMI population undergoing PCI, the most
ommon antithrombotic strategy continues to be heparin
ith a GPI. Contemporary trials confirm the safety of
ivalirudin or heparin alone in patients undergoing PCI
4,5,12–14); however, this strategy was used only 30% of the
ime. The strategy of heparin or bivalirudin alone without a
PI was more common among patients at higher risk of
leeding than at lower risk, and despite this higher-risk,
atients treated with heparin or bivalirudin without a GPI
ad less major bleeding. In addition, patients treated with
ivalirudin alone had lower mortality. A sensitivity analysis
liminating patients who received excess doses of anti-
hrombins did not alter these findings. The addition of
ne Bleeding and Mortality Risk Groups
tor; Hep alone  heparin only; Hep/GPI  heparin/glycoprotein IIb/IIIaaseli
inhibilopidogrel occurred in 80% overall and was more often
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674iven before PCI in those treated with heparin or bivaliru-
in alone, suggesting that it was part of the strategy in these
atients. We also observed that even among those at low
isk of bleeding there was a paradoxical greater use of GPI
n those at lower risk for mortality (75.7% vs. 72.7%). These
bservations underscore that safety profiles demonstrated in
linical trials are important in the translation of evidence
nto practice. Clinicians select strategies with lower treat-
ent associated bleedings and preferentially apply them to
atients at higher risk of bleeding in practice.
Several clinical trials have demonstrated the superior
leeding profile of bivalirudin with provisional GPI over
ntithrombins with planned GPI in similar acute coronary
yndromes populations. First, among 4,098 patients with
nstable or post-infarction angina undergoing angioplasty,
hose treated with bivalirudin demonstrated similar isch-
mic events (11.4% vs. 12.2%) but less bleeding (3.8% vs.
.8%) compared with heparin (15). The REPLACE (Ran-
omized Evaluation in PCI Linking Angiomax to Reduced
Table 2. Acute Medications and In-Hospital Procedures According to Antit
Hep Alone
(n  1,365)
Biva
(n 
Medications within 24 h (%)
Aspirin 97
Clopidogrel 73
Beta-blocker 93
ACE inhibitor 44
Statin 60
Any heparin 100
Number of diseased vessels (%)
0 or 1 42
2 31
3 27
Cath within 24 h of arrival (%) 55
Overall type of PCI stent (%)
Drug-eluting 63
Bare-metal 36
PCI within 24 h of arrival (%) 52
Assessment of LVEF (%) 91
LVEF (%)
50, normal 60
40–49, mild dysfunction 21
25–39, moderate dysfunction 15
25, severe dysfunction 4
CABG (%) 2
Time from hospital presentation to
Cath (h)* 24 (12, 47) 21
PCI (h)* 26 (13, 50) 22
CABG (h)* 69 (46, 143) 166
First ECG (min)* 11 (5, 21) 10
Medication groups are determined by antithrombotic strategy at time of PCI. *Continuous variable
ACE angiotensin-converting enzyme; Cath cardiac catheterization; ECG electrocardiogramlinical Events)-2 trial of 6,010 patients undergoing urgent wr elective PCI demonstrated that the 30-day composite
nd point of death, MI, repeat revascularization, and in-
ospital major bleeding was similar between patients treated
ith bivalirudin alone with provisional GPI or heparin/GPI
9.2% vs. 10%); however, bleeding rates were lower with
ivalirudin alone (13). Similarly, in the ISAR-REACT
Intracoronary Stenting and Antithrombotic Regimen:
apid Early Action for Coronary Treatment)-3 trial, biva-
irudin demonstrated similar ischemic benefits with signif-
cantly less bleeding when compared with unfractionated
eparin (14). In the ACUITY (Acute Catheterization and
rgent Intervention Triage Strategy) trial, bivalirudin alone
as compared with enoxaparin or unfractionated heparin
lus GPI and bivalirudin plus GPI (4,5). No differences in
he composite end point of 30-day death, MI, or unplanned
evascularization were observed across the 3 arms, but
ivalirudin alone was associated with significantly lower
ates of bleeding when compared with combined therapy. In
his population, longer times to catheterization and PCI
otic Treatment Among PCI Patients
e
1)
Hep/GPI
(n  7,086)
Bival/GPI
(n  863) p Value
99 98 0.0006
81 82 0.0001
95 94 0.001
50 50 0.0001
66 67 0.0001
94 81 0.0001
0.004
42 38
33 36
25 25
75 71 0.0001
0.0003
61 69
38 30
73 67 0.0001
94 95 0.0001
0.0021
61 60
23 23
13 12
3 4
2 0.8 0.0002
) 16 (4, 27) 17 (6, 33) 0.0001
) 17 (4, 28) 19 (7, 39) 0.0001
1) 79 (47, 115) 56 (40, 105) NS
9 (5, 19) 9 (5, 18) 0.001
esented as median (25th, 75th percentile).
 left ventricular ejection fraction; other abbreviations as in Table 1.hromb
l Alon
1,77
97
78
93
44
61
77
39
33
29
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64
35
59
92
64
18
14
3
0.3
(10, 40
(10, 43
(36, 20
(5, 22)
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675roups, but time to catheterization and PCI for the anticoag-
lant with GPI groups still averaged approximately 18 h. The
afety of bivalirudin was found to be relatively greater (approx-
mately 50%) in the elderly population (age75 years) under-
oing PCI due to their higher baseline risk of bleeding (16).
xcess dosing has also been suggested as an explanation for the
ncreased bleeding among patients treated with GPI (17). In
he present study, we observed that major bleeding across
reatment strategies persisted after eliminating patients with
xcess dosing. Higher-risk profiles in the community (com-
ared with a trial population) might accentuate observed
reatment differences. The application of these strategies across
roups that differ in comorbidity extends the observed safety
dvantage of bivalirudin or heparin alone in clinical practice.
Timing of therapy might also play a role in treatment-
ssociated bleeding. For example, the optimal timing of
Table 3. Use of Antithrombotic Agents According to Start Time of PCI
Hep
Alone
Bival
Alone Hep/GPI Bival/GPI p Value
Clopidogrel (%) 0.001
Peri PCI 45 48 61 51
Before PCI 55 52 39 49
UFH (%) 0.001
Peri PCI 22 9 27 12
Before PCI 78 91 73 88
Low-molecular-weight
heparin (%)
0.02
Peri PCI 6 10 9 7
Before PCI 94 90 91 93
Bivalirudin (%)
Peri PCI n/a 97 n/a 96 0.7
Before PCI n/a 3 n/a 4
GPI (%) 0.19
Peri PCI n/a n/a 54 55
Before PCI n/a n/a 46 45
Before PCIwas frompresentation to 1hbefore the PCI procedure. Peri PCIwas from1hbefore the
procedure to any time after the procedure.
n/anot applicable due to antithrombotic treatment definition; other abbreviations as in Table 1.
Table 4. Crude Rates for In-Hospital Outcomes by Antithrombotic Strategy
Hep Alone
(n  1,365)
Bival Alon
(n  1,771
Death 1.3 0.7
Re-MI 1.3 0.9
Death or re-MI 2.4 1.5
Cardiogenic shock 2.3 1.1
Heart failure 4.5 4.1
Stroke 0.0 0.2
Major bleeding 6.5 5.7
Non-CABG transfusions 5.1 4.9
Data presented as %.Re-MI recurrent myocardial infarction; other abbreviations as in Table 1.PI was recently evaluated in the EARLY ACS (Early
lycoprotein IIb/IIIa Inhibition in Non–ST-segment Ele-
ation Acute Coronary Syndrome) trial. The study com-
Hep/GPI
(n  7,086)
Bival/GPI
(n  863) p Value
1.3 1.3 NS
1.1 2.3 0.006
2.3 3.2 0.04
2.2 2.2 0.025
3.5 3.6 NS
0.3 0.1 NS
8.8 10.7 0.0001
5.0 6.4 NS
A
B
Figure 2. Adjusted Odds Ratio for Major Bleeding and
In-Hospital Mortality by Antithrombotic Strategy
Adjusted odds ratio (95% conﬁdence interval) for (A) major bleeding and
(B) in-hospital mortality by antithrombotic strategy. The reference group is
Hep/GPI. Abbreviations as in Figure 1.e
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676ared early (12 h before catheterization) eptifibatide to
elayed provisional eptifibatide among 9,492 patients with
on–ST-segment elevation acute coronary syndromes (6).
o significant differences in death or MI at 30 days were
oted between early and delayed eptifibatide (9.3% vs.
0.0%, respectively), but more major bleeding and transfu-
ions were observed in the early-eptifibatide group. Similar
ndings were previously observed by the ACUITY investi-
ators (18). In 9,207 patients with moderate-to-high-risk
cute coronary syndromes undergoing an invasive treatment
trategy, the use of GPI at the time of the angioplasty
delayed) was associated with a nonsignificant increase in
he composite outcome of death, MI, and unplanned
evascularization for ischemia at 30 days but significantly
ess major and minor bleeding when compared with those
atients receiving GPI upstream (early). Therefore, the
eferred use of GPI resulted in similar rates of net clinical
utcomes but in better safety compared with upstream use.
lthough the provisional use of GPI is not the focus of the
resent analysis, we note in our population approximately
5% of those who received GPI did so before PCI as an
pstream strategy.
Clopidogrel is recommended in all patients in advance of
lanned PCI and is particularly important when GPI is not
art of the treatment strategy (19). It has been shown that
re-treatment with clopidogrel is clinically important in
CI patients treated with bivalirudin alone (19). Patients
reated with bivalirudin alone who did not receive clopi-
Figure 3. Unadjusted Rate of Major Bleeding Stratified by CRUSADE Bleed
CRUSADE  Can Rapid risk stratiﬁcation of Unstable angina patients Suppress AD
American Heart Association guidelines; other abbreviations as in Figure 1.ogrel at the time of PCI experienced more ischemic events rompared with those who received clopidogrel. In our study,
he majority of patients received clopidogrel early; however,
ts recommended use in advance of PCI was lacking in
pproximately 20%. Patients treated with heparin or biva-
irudin alone were slightly more likely to receive clopidogrel
efore PCI compared with those treated with either drug
lus a GPI, suggesting that it might have been part of the
nitial treatment strategy. Furthermore, the bivalirudin-
lone group received more clopidogrel (78%) than the
eparin-alone group (73%), and this fact could have played
role in the lower mortality rates in the bivalirudin-alone
roup. Overall, focus upon better upstream use of clopi-
ogrel might further improve outcomes, particularly among
atients treated with heparin or bivalirudin alone.
tudy limitations. Our study has several limitations. First,
CTION sites volunteered for this national quality im-
rovement initiative and might not be representative of all
.S. practice. Second, all outcome comparisons were obser-
ational and might be subject to treatment selection bias.
lthough we did adjust our findings for most of the key
easured confounders, unmeasured confounders could not
e accounted for, and therefore causal relationships between
reatment strategies and outcomes cannot be established. In
ddition, we observed some imbalances—such as time to
ardiac catheterization/PCI and troponin levels—among
he different groups for which we did not adjust. Third, we
eport in-hospital outcomes; therefore, caution should be
aken when considering the long-term implications of these
ore Risk and Antithrombotic Strategy
outcomes with Early implementation of the American College of Cardiology/ing Sc
verseesults. Fourth, we did not collect information about up-
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677tream versus bailout use of GPI, so all GPI use was
onsidered together. Finally, we could not account for the
xact timing or switching and crossing-over of antithrom-
otic strategies. For the sake of simplicity, strategies imple-
ented before PCI were not considered further in this
escriptive analysis.
onclusions
tandard practice in patients with NSTEMI undergoing
CI is to use heparin/GPI, yet approximately 30% of
STEMI patients receive heparin alone or bivalirudin alone
t the time of PCI. There is a selection bias in favor of use
f antithrombins alone in those patients at higher baseline
isk for bleeding. This selection process seems to benefit this
igh-risk group, who go on to have lower rates of major
leeding during their hospital stay.
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